Novartis Drags DRL to US Court Over Patent Infringement

As per Novartis’ petition filed on August 20 at the District Court of Delaware, DRL infringed its patents pertaining to the generic version of its anti-cancer drug -- Gleevec.

Published: 09th September 2014 06:00 AM  |   Last Updated: 09th September 2014 09:36 AM   |  A+A-

NOVS

HYDERABAD: Basel-headquartered Novartis Pharmaceuticals Corporation and Novartis AG dragged Dr Reddy’s Laboratories Ltd (DRL) and its US subsidiary Dr Reddy’s Laboratories Inc to the US court over alleged patent infringement.

As per Novartis’ petition filed on August 20 at the District Court of Delaware, DRL infringed its patents pertaining to the generic version of its anti-cancer drug -- Gleevec.

“DRL’s commercial manufacture, use, offer to sell or sale of its Imatinib Mesylate ANDA Tablets, prior to the expiration of the ’051 Patent and the RE932 Patent, would constitute infringement of the ’051 Patent and the RE932 Patent under 35 U.S.C. § 271,” Novartis said adding that the company will be substantially and irreparably damaged and harmed if DRL’s infringement is not enjoined.

According to Novartis, DRL sought the FDA’s approval to manufacture, use, offer to sell or sale of bioequivalents of Novartis’ 100 mg and 400 mg imatinib mesylate Gleevec® tablets prior to their expiration of patents.

It urged the Court to issue a judgment and decree that the ’051 Patent and the RE932 Patent are valid and enforceable and declare that DRL’s making, using, sell ing, offering to sell or importing its Imatinib Mesylate ANDA Tablets will infringe the ’051 Patent and the RE932 patent.

It also sought a judgment permanently enjoining DRL from making, using, selling, offering to sell, or importing its Imatinib Mesylate ANDA tablets until after expiration the said patents besides seeking damages resulting from such infringement.

It may be noted that early this year, Novartis filed a similar suit against DRL for submitting an ANDA seeking FDA’s approval to engage in the commercial manufacture, use and sale of oral capsules containing 100 mg of imatinib mesylate, imatinib mesylate oral capsules and EQ 100 mg Base, prior to the expiration of its patents.

Stay up to date on all the latest Business news with The New Indian Express App. Download now
(Get the news that matters from New Indian Express on WhatsApp. Click this link and hit 'Click to Subscribe'. Follow the instructions after that.)

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp